First in Market: MEXC to List KOD Stock Futures With 0-Fee Trading on Sep 28

To further expand trading opportunities and enhance your Futures trading experience, MEXC will launch KOD Stock Futures on the Futures market. This new listing offers a flexible and efficient way to gain exposure to one of the most prominent equities. Futures trading will be available immediately upon listing, with Futures Grid Bot strategies available within 5 minutes of listing.

Futures Trading Details

Feature
Details
Trading Pair
KODUSDT
Listing Time
Sep 28, 2026, 15:50 (UTC)
Max Leverage
20x
Margin Mode
Cross & Isolated
Trading Hours
24/7

What Is KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc.

🎉 Limited-Time Offer: Enjoy 0 Trading Fees

Enjoy 0 trading fees on the Stock Futures for a limited time! This fee update only applies to select users in specific regions. Please check your account's fee page or trading page for the latest rates.

Related Articles:

Important Notes
• Corporate actions (e.g., dividends, stock splits, reverse splits) may cause sharp price movements. Depending on market conditions, the platform may implement measures including early settlement or position adjustments. Users should monitor relevant announcements and manage risks to avoid unexpected losses.
• Stocks may trigger a circuit breaker due to market conditions. If triggered, trading will be halted and orders cannot be executed. No liquidation will occur, and existing orders can still be canceled. Please monitor the market, manage your positions, and refer to the official circuit breaker announcement for details.
• Availability of Stock Futures may vary by region due to regulatory restrictions. Certain jurisdictions may not support these products. Please refer to the User Agreement for full details.
• MEXC reserves the right to adjust the list of supported regions at any time based on operational and compliance considerations.
Coin Icon
Sign up now to receive 10,000 USDT in new user rewards

Subscribe to MEXC Digest

Weekly market moves, listings & insights, straight to your inbox.
By subscribing, you agree to receive MEXC newsletters and email updates, and to our Privacy Policy. The content provided is for informational purposes only and does not constitute investment advice.

Join MEXC on Telegram

Get the latest listings, events, and updates in real time, straight from our official Telegram channel.

First in Market: MEXC to List KOD Stock Futures With 0-Fee Trading on Sep 28

To further expand trading opportunities and enhance your Futures trading experience, MEXC will launch KOD Stock Futures on the Futures market. This new listing offers a flexible and efficient way to gain exposure to one of the most prominent equities. Futures trading will be available immediately upon listing, with Futures Grid Bot strategies available within 5 minutes of listing.

Futures Trading Details

Feature
Details
Trading Pair
KODUSDT
Listing Time
Sep 28, 2026, 15:50 (UTC)
Max Leverage
20x
Margin Mode
Cross & Isolated
Trading Hours
24/7

What Is KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc.

🎉 Limited-Time Offer: Enjoy 0 Trading Fees

Enjoy 0 trading fees on the Stock Futures for a limited time! This fee update only applies to select users in specific regions. Please check your account's fee page or trading page for the latest rates.

Related Articles:

Important Notes
• Corporate actions (e.g., dividends, stock splits, reverse splits) may cause sharp price movements. Depending on market conditions, the platform may implement measures including early settlement or position adjustments. Users should monitor relevant announcements and manage risks to avoid unexpected losses.
• Stocks may trigger a circuit breaker due to market conditions. If triggered, trading will be halted and orders cannot be executed. No liquidation will occur, and existing orders can still be canceled. Please monitor the market, manage your positions, and refer to the official circuit breaker announcement for details.
• Availability of Stock Futures may vary by region due to regulatory restrictions. Certain jurisdictions may not support these products. Please refer to the User Agreement for full details.
• MEXC reserves the right to adjust the list of supported regions at any time based on operational and compliance considerations.
Coin Icon
Sign up now to receive 10,000 USDT in new user rewards

Subscribe to MEXC Digest

Weekly market moves, listings & insights, straight to your inbox.
By subscribing, you agree to receive MEXC newsletters and email updates, and to our Privacy Policy. The content provided is for informational purposes only and does not constitute investment advice.

Join MEXC on Telegram

Get the latest listings, events, and updates in real time, straight from our official Telegram channel.
Stay up-to-date on the latest MEXC listings, delistings, trading events, and product updates. Discover new tokens, Launchpad projects, Earn opportunities, AI-powered tools, and futures trading enhancements on the MEXC platform.Stay up-to-date on the latest MEXC listings, delistings, trading events, and product updates. Discover new tokens, Launchpad projects, Earn opportunities, AI-powered tools, and futures trading enhancements on the MEXC platform.